Company||Analyst: DIFF Corporate Industry Analysis Team
AbbVie Inc. (ABBV): Beyond the Humira Cliff, A High-Stakes Bet on a New Growth Formula | Corporate Analysis
AbbVie confronts its post-Humira reality with a strategic pivot into high-growth sectors like obesity and psychiatry. While revenue growth shows resilience, declining profitability and a sharp valuation reset signal significant market uncertainty. The company's future now hinges on the successful execution of its nascent, yet promising, blockbuster pipeline.
0
2